SecBot SecBot

MDWD drug pipeline

MediWound Ltd. · 2 rated drugs
$13.55
+5.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±15.7%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.

EscharEx bromelain-based enzymatic debridement therapy Updated Nov 5

What to watch

The next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.

Bull case
  • EscharEx has demonstrated superiority over the market-leading enzymatic debridement product SANTYL ($360M+ annual US sales) in Phase 2 head-to-head data, showing advantages in debridement, granulation tissue promotion, and time to wound closure.
  • An independent DSMB reviewed the Phase 3 VALUE trial in September 2026 and recommended continuation without modification, finding no safety concerns.
  • Updated US market assessment including pressure ulcers estimates peak annual sales potential of $1.05 billion for EscharEx, targeting a $2.5B+ total addressable market.
Bear case
  • Phase 3 VALUE trial enrollment has been slower than initially anticipated, pushing the interim assessment from mid-2026 to Q1 2027.
  • EscharEx is still years from potential approval (Phase 3 readout not expected until 2H 2027 at earliest, then FDA filing and review), meaning no near-term revenue from this asset.
  • MediWound's Q2 2026 revenue fell 45.6% year-over-year to $3.1M, and the company remains unprofitable, requiring continued cash burn to fund the EscharEx program.
● neutral
Impact
PhasePhase 1/2 (completed)
Time to marketYears away. MW005 has completed Phase 1/2 testing but has no disclosed Phase 2/3 trial start or regulatory pathway, making any timeline to potential approval speculative and likely several years off if development proceeds.

MW005 Updated Nov 5

What to watch

MW005 has no scheduled regulatory or pivotal-readout catalyst in the next 12 months. The next company-wide event is Q3 2026 earnings on November 12, 2026, but that is a financial update, not a drug-specific binary. Watch for any announcement from MediWound on next-phase development plans for MW005, which would be the first signal of meaningful pipeline progression.

Bull case
  • Phase 1/2 data showed MW005 was safe, well-tolerated, and achieved complete clinical and histological clearance of target lesions in low-risk BCC patients, offering a potential non-surgical topical alternative to excision.
  • MW005 shares the same active pharmaceutical ingredient (proteolytic enzymes enriched in bromelain) as MediWound's approved product NexoBrid, leveraging an established platform with regulatory precedent.
  • Analyst consensus on MDWD is bullish: 8 Buy, 3 Strong Buy, 1 Hold, 0 Sell, with a mean price target of $30.67 (approximately 130% implied upside from the $13.33 close).
Bear case
  • MW005 is an early-stage (Phase 1/2 completed) asset with no disclosed next-phase trial initiation or regulatory path, making its timeline to commercialization uncertain and likely years away.
  • MediWound's primary pipeline focus and capital allocation is on the EscharEx Phase 3 VALUE trial and its commercial NexoBrid business, leaving MW005 as a lower-priority pipeline asset with limited near-term value inflection.
  • The company completed a $17.25M stock offering on November 5, 2026, diluting existing shareholders, and the stock fell 6.1% on the day to $13.33, well below the mean analyst target of $30.67.

Other drugs in filings and trials

no drug report yet
  • NEXOBRID Last: Approval · Dec 28, 2022

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Dec 28, 2022NEXOBRIDApproval+15.7%+9.4%